Gilead Sciences’ Phase III study (Study 116) of idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early. The decision followed a recommendation by an independent Data Monitoring Committee (DMC) and is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab compared to those receivin...